| scholarly article | Q13442814 |
| P2093 | author name string | Baptist Gallwitz | |
| Karin Helsberg | |||
| Oliver Bachmann | |||
| Helmut Petto | |||
| Bernd Becker | |||
| Thomas Segiet | |||
| Natalie Peters | |||
| Michael Böhmer | |||
| Andrea Mölle | |||
| Karsten Milek | |||
| P2860 | cites work | A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes. | Q51397569 |
| A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. | Q51483637 | ||
| Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetolo | Q80035754 | ||
| Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea | Q83329973 | ||
| Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
| Standards of medical care in diabetes--2010. | Q33554238 | ||
| The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study | Q33579765 | ||
| Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia | Q36108419 | ||
| Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card | Q41824843 | ||
| Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association | Q43252028 | ||
| Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial | Q46308233 | ||
| Standards of medical care in diabetes--2008. | Q46828447 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| preproinsulin | Q7240673 | ||
| hypoglycemia | Q202758 | ||
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 604-606 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia | |
| P478 | volume | 34 |
| Q26765155 | A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus |
| Q51278208 | A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. |
| Q39870068 | Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials |
| Q34598490 | Comparison between two generic questionnaires to assess satisfaction with medication in chronic diseases. |
| Q36725186 | Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial |
| Q38154679 | Composite endpoints in trials of type-2 diabetes |
| Q27011627 | Effects of GLP-1 on appetite and weight |
| Q36584204 | Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. |
| Q47769217 | Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials |
| Q35996636 | Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis |
| Q36011993 | Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis |
| Q36071183 | Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials |
| Q28088578 | Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus |
| Q36877205 | Evolution of exenatide as a diabetes therapeutic |
| Q36538817 | Exenatide extended-release; clinical trials, patient preference, and economic considerations |
| Q38179267 | Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus |
| Q30558739 | Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index |
| Q92649404 | GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective |
| Q38824034 | Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research |
| Q34265490 | Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis |
| Q38951755 | Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study. |
| Q37577129 | How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment |
| Q36520655 | Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis |
| Q38140803 | Incretin-based therapies: focus on effects beyond glycemic control alone |
| Q38214060 | Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents |
| Q36782811 | Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas |
| Q90625078 | Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis |
| Q51249870 | Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes. |
| Q48317531 | Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials |
| Q28084768 | Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies |
| Q38235219 | Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials |
| Q31066859 | Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program |
| Q35780935 | Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials |
| Q92432095 | THE EFFECT OF EXENATIDE THERAPY IN PREVIOUSLY INSULIN-TREATED TYPE 2 DIABETIC PATIENTS |
| Q88550258 | The Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Type 2 Diabetes |
| Q28078225 | The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review |
| Q38137027 | The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis |
| Q35760288 | The role of incretin therapy at different stages of diabetes |
| Q38634679 | Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review |
| Q38006504 | Update on incretin hormones |
| Q54687755 | Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. |
Search more.